KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Receivables (2016 - 2025)

Historic Receivables for Neogenomics (NEO) over the last 16 years, with Q4 2025 value amounting to $159.2 million.

  • Neogenomics' Receivables rose 571.03% to $159.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $159.2 million, marking a year-over-year increase of 571.03%. This contributed to the annual value of $159.2 million for FY2025, which is 571.03% up from last year.
  • Per Neogenomics' latest filing, its Receivables stood at $159.2 million for Q4 2025, which was up 571.03% from $155.3 million recorded in Q3 2025.
  • Neogenomics' 5-year Receivables high stood at $159.2 million for Q4 2025, and its period low was $105.3 million during Q1 2021.
  • Moreover, its 5-year median value for Receivables was $128.7 million (2023), whereas its average is $130.8 million.
  • Over the last 5 years, Neogenomics' Receivables had its largest YoY gain of 2152.46% in 2021, and its largest YoY loss of 152.98% in 2021.
  • Over the past 5 years, Neogenomics' Receivables (Quarter) stood at $114.1 million in 2021, then increased by 6.6% to $121.6 million in 2022, then grew by 7.91% to $131.3 million in 2023, then increased by 14.76% to $150.6 million in 2024, then rose by 5.71% to $159.2 million in 2025.
  • Its Receivables stands at $159.2 million for Q4 2025, versus $155.3 million for Q3 2025 and $153.1 million for Q2 2025.